OSI Pharmaceuticals
OSI Pharmaceuticals is a biotechnology company that specializes in the discovery, development, and commercialization of high-quality, innovative, and targeted medicines to meet critical patient needs in oncology, diabetes, and obesity. The company was founded in 1983 and is headquartered in Melville, New York.
History[edit | edit source]
OSI Pharmaceuticals was founded in 1983 by a group of scientists and entrepreneurs. The company initially focused on the development of novel therapeutic agents for the treatment of cancer and diabetes. In 1996, OSI Pharmaceuticals became a publicly traded company on the NASDAQ stock exchange.
Products[edit | edit source]
OSI Pharmaceuticals' most successful product to date is Tarceva, a drug used for the treatment of non-small cell lung cancer and pancreatic cancer. Tarceva was approved by the Food and Drug Administration (FDA) in 2004.
Acquisition by Astellas Pharma[edit | edit source]
In 2010, OSI Pharmaceuticals was acquired by Astellas Pharma, a Japanese pharmaceutical company, for $4 billion. The acquisition was part of Astellas' strategy to expand its oncology portfolio.
Research and Development[edit | edit source]
OSI Pharmaceuticals has a robust research and development program, with a focus on oncology, diabetes, and obesity. The company's R&D efforts are aimed at discovering and developing innovative medicines that can improve patient outcomes and quality of life.
See Also[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD